603 Page 1 30-Sep-2026To Company Name/SchemeACN/ARSN1. Details of substantial holder (1)NameACN/ARSN (if applicable)The holder became a substantial holder on28/09/20262. Details of voting powerThe total number of votes attached to all the voting shares in the company or voting interests in the...
Becoming a substantial holder
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Mesoblast
- FDA Approves New Potency Assay for Commercial Ryoncil
- Ceasing to be a substantial holder
- Annual Report for Fiscal Year Ending June 30, 2026 (Form 20-F)
- Mesoblast Reports Substantial Revenue Growth to US$120M
- MSB Annual Financial Results and Operational Update
Later from Mesoblast
- Appendix 4G and Corporate Governance Statement
- Notice of Annual General Meeting and Proxy Form
- Annual Report to Shareholders
- Application for quotation of securities - MSB
- Notification regarding unquoted securities - MSB
